Nivolumab trials for Melanoma

All Nivolumab trials · All Melanoma trials

Phase breakdown

Recruiting trials studying Nivolumab for Melanoma

• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 33 locations
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of TRK-950 in Patients With Advanced Solid Tumors
  NCT05423262 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
  NCT04511013 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 331 locations
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
  NCT04741997 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
  NCT03340129 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 9 locations
• Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
  NCT06163820 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
  NCT05136196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
• Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
  NCT06319196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
  NCT06265285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cryoablation+Ipilimumab+Nivolumab in Melanoma
  NCT05779423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
  NCT03685890 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
  NCT04562129 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 211 locations
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
  NCT07422779 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
  NCT05896839 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
  NCT06240143 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
  NCT04697576 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
  NCT05655312 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 13 locations
• MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
  NCT07092670 · Phase: Not specified · Ages: Up to 40 Years · Sex: Female · 10 locations
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
  NCT05076760 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
  NCT05629546 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
  NCT06365619 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
  NCT06295159 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
  NCT07223424 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
  NCT05098210 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
  NCT06683755 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
  NCT05704647 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
  NCT06794775 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
  NCT05652673 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
  NCT05267626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
  NCT05498792 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
  NCT07155317 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 81 locations
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
  NCT07504796 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Nivolumab for Melanoma?

38 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.